Janssen to Address NICE's Concerns Following Another English Funding No For Spravato
UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.
You may also be interested in...
Health technology assessment body NICE has now rejected Spravato for the third time, saying it has concerns over the clinical evidence and economic model for the drug, for treating adults with major depression that is resistant to treatment.
Discrepancy in access to Janssen’s antidepressant nasal spray between patients in Scotland and those in England and the rest of the UK may be due to the differences in methodologies and approaches used by the health technology assessment bodies.
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.